Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RNTX Hot Sheet
Join SI Premium – FREE
Rein Therapeutics Inc. (NASDAQ: RNTX) reported Q2 EPS of ($0.10), $0.39 better than the analyst estimate of ($0.49).
For earnings history and earnings-related data on Rein Therapeutics Inc. (RNTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real Industry (RELY) Tops Q3 EPS by 15c; offers guidance
- MGIC Investment (MTG) Tops Q3 EPS by 4c
- Solid Biosciences (SLDB) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
